Thus, by building upon early observations of anti-hyperglycemic actions of GLP-1 and Gila monster exendin-4, exenatide (synthetic exendin-4) has been successfully developed into a first-in-class diabetes therapeutic. The gene discussed is GLP1R; the disease is diabetes mellitus.